scispace - formally typeset
N

Nathan F. Dieckmann

Researcher at Oregon Health & Science University

Publications -  110
Citations -  4958

Nathan F. Dieckmann is an academic researcher from Oregon Health & Science University. The author has contributed to research in topics: Medicine & Randomized controlled trial. The author has an hindex of 28, co-authored 92 publications receiving 4024 citations. Previous affiliations of Nathan F. Dieckmann include University of Oregon.

Papers
More filters
Journal ArticleDOI

How numeracy influences risk comprehension and medical decision making.

TL;DR: Four theoretical approaches (psychophysical, computational, standard dual-process, and fuzzy trace theory) are outlined, their implications for numeracy are reviewed, and avenues for future research are pointed to.
Journal ArticleDOI

Less is more in presenting quality information to consumers.

TL;DR: Results of three studies support the idea that “less is more” when presenting consumers with comparative performance information to make hospital choices, and have important implications for the sponsors of comparative quality reports designed to inform consumer decision making in health care.
Journal ArticleDOI

Numeracy Skill And The Communication, Comprehension, And Use Of Risk-Benefit Information

TL;DR: This work reviews the literature and examines what can be done to help less numerate people act more effectively and take charge of their health.
Journal ArticleDOI

Development and Testing of an Abbreviated Numeracy Scale: A Rasch Analysis Approach

TL;DR: A shorter, psychometrically improved measure of numeracy—the ability to understand, manipulate, and use numerical information, including probabilities, is developed, which is the first to present the psychometric properties of several popular numeracy measures across a diverse sample of ages and educational level.
Journal ArticleDOI

Falls, Functioning, and Disability Among Women With Persistent Symptoms of Chemotherapy-Induced Peripheral Neuropathy

TL;DR: CIPN must be assessed earlier in the clinical pathway, and strategies to limit symptom progression and to improve function must be included in clinical and survivorship care plans.